HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Diatrizoate

HCID 2140
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
117-96-4
Standard SMILES
CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
InChIKey
YVPYQUNUQOZFHG-UHFFFAOYSA-N
Molecular formula
C11H9I3N2O4
Average molar mass
613.91 g/mol
Monoisotopic mass
613.76965077

Overview

Amidotrizoic acid is a member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography. It has a role as a xenobiotic, a radioopaque medium and an environmental contaminant. It is a member of acetamides, a member of benzoic acids and an organoiodine compound. It is a conjugate acid of an amidotrizoic acid anion.

Names & identifiers

Preferred name
Diatrizoate
IUPAC
3,5-diacetamido-2,4,6-triiodobenzoic acid
English name
Diatrizoic acid
Molecular formula
C11H9I3N2O4
Molecular weight
613.91

Names & synonyms

Diatrizoic acid117-96-4amidotrizoic acidDIATRIZOATEUrogranoic acidAmidotrizoateUrografin acidUrotrastDiatDiatriazoateDiatrizoesaureAcidum amidotrizoicum
Show more names
DiatrizoicodistonNSC-61815triombrinNSC 262168
3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acidAcide amidotrizoiqueUrothrast2,4,6-Triiodo-3,5-diacetamidobenzoic acidDTXSID0044521Acidum diacetylaminotrijodbenzoicumdiatrizoic acid (anhydrous)5UVC90J1LK

Database identifiers

CAS
117-96-4、50978-11-5
PubChem CID
2140
DTXSID
DTXSID0044521
ChEMBL
CHEMBL1201220
ChEBI
CHEBI:53691
UNII
5UVC90J1LK
EC Number
204-223-6
Nikkaji
J5.294I

Properties

Computed structural properties

XLogP
1.8
Topological polar surface area
95.5 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
4
Rotatable bonds
3
Heavy atoms
20
Formal charge
0
Complexity
390

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

SpringerMaterials PropertiesNuclear quadrupole resonance spectroscopy
LogP · 2 items

3.3

-1.05

Color/Form · 3 items

WHITE POWDER

Crystals from dilute dimethylformide

Crystals from ethanol (aqueous)

Solubility · 3 items

VERY SLIGHTLY SOL IN WATER, ALCOHOL; SOL IN DIMETHYLFORMAMIDE, ALKALI HYDROXIDE SOLUTIONS

In water, 5.0X10+5 mg/L at 25 °C

1.07e-01 g/L

Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

Diagnostic agents > Radiocontrast media

DecompositionWhen heated to decomposition it emits very toxic fumes of /oxides of nitrogen and iodine/.
Melting Point

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 10% (1 of 10) of reports.

Danger

H317 (90%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 10 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 3 items

Chemical: Benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo-

Status: Active Update: 03-12-2019 https://echa.europa.eu/registration-dossier/-/registered-dossier/11883

Diatrizoic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

FDA Requirements · 5 items

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl diatrizoate meglumine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Diatrizoate meglumine/

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl diatrizoate sodium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Diatrizoate sodium/

The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Diatrizoate meglumine is included on this list. /Diatrizoate meglumine/

Chemistry & industry

Pharmacology

ATC Code · 3 items

V - Various

QV - Various

V08AA01

Pharmacodynamics · 1 item

Diatrizoate is the most commonly used water-soluble, iodinated, radiopaque x-ray contrast medium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.

Mechanism of Action · 2 items

Diatrizoate is an iodine-containing X-ray contrast agent. Iodated contrast agents were among the first contrast agents developed. Iodine is known to be particular electron-dense and to effectively scatter or stop X-rays. A good contrast agent requires a high density of electron-dense atoms. Therefore, the more iodine, the more "dense" the x-ray effect. Iodine based contrast media are water soluble and harmless to the body. These contrast agents are sold as clear colorless water solutions, the concentration is usually expressed as mg I/ml. Modern iodinated contrast agents can be used almost anywhere in the body. Most often they are used intravenously, but for various purposes they can also be used intraarterially, intrathecally (the spine) and intraabdominally - just about any body cavity or potential space.

Radiocontrast medium induced nephrotoxicity is a major clinical problem. There is considerable interest in reducing the incidence of acute renal failure due to the use of radiocontrast media (RCM). Reduction of renal blood flow and direct toxic effect on renal tubular epithelial cells have been postulated as major causes of RCM nephropathy. Understanding the molecular mechanisms by which RCM cause cell damage may allow the development of pharmacological therapy to prevent their nephrotoxicity. In this work we have investigated the signaling pathways that may be affected by RCM. The incubation of human renal tubular proximal cells with sodium diatrizoate, iopromide and iomeprol caused a marked dephosphorylation of the kinase Akt on Ser473 within 5min of incubation. RCM also caused a decrease in cell viability, which was substantially alleviated by transfecting the cells with a constitutively active form of Akt. Further downstream targets of Akt, including the Forkhead family of transcription factors FKHR and FKHRL1, were also dephosphorylated by RCM at Thr24 and Thr32, respectively. The P70S6 kinase was also dephosphorylated at Thr389 and Ser371 by RCM. However there was a more dramatic decrease in phosphorylation of the phosphorylated form of mammalian target of rapamycin (mTOR) and of the extracellular-signal regulated kinases (ERK) 1/2 caused by sodium diatrizoate than by iopromide. These results demonstrate the effect of RCM on some intracellular signaling pathways that may allow understanding of the mechanism of their toxicity and may allow the development of strategies to overcome their adverse effects.

Related reactions

3 records
New reaction record
HRID 964370 reaction equation
HRID 964370As reactant
HRID 1149371 reaction equation
HRID 1149371As reactant
HRID 1956891 reaction equation
HRID 1956891As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
· 2 items

>250

> 300 °C

Physical DescriptionSolid
Stability/Shelf LifePreparations containing diatrizoate sodium should be protected from strong light.
Collision Cross Section · 3 items

179.4 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID0044521]

176.3 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

175.26 Ų [M+H]+

Other Experimental Properties · 3 items

Rhombic needles. Slightly sweet taste; melting point 189-193 °C (decomposition); solubility in water at 20 °C: 89 g/100 mL /Meglumine diatrizoate/

pH between 6.0 & 7.6 /Diatrizoate Meglumine/

SOLN OF DIATRIZOATE SODIUM ARE CONSIDERABLY LESS VISCOUS THAN THOSE PREPD FROM DIATRIZOATE MEGLUMINE /SODIUM DIATRIZOATE/

Physicochemical properties

Melting point
300 °C · >300°C
Boiling point
614.1 · 614.1±55.0 °C(Predicted)
Density
2.4079 · 2.4079 (estimate)
vapor pressure
0 Pa · 0Pa at 20℃
storage temp.
Keep in dark place,Inert atmosphere,Room temperature
solubility
Soluble in Methanol.
pka
0.92 · 0.92±0.10(Predicted)
form
Solid
color
White to Off-White
Water Solubility
500 g/L · 500g/L(25 ºC)
Merck
14 · 14,2992
Henry's Law Constant
3.5 · 3.5×1012 mol/(m3Pa) at 25℃, Zhang et al. (2010)
Stability
Light Sensitive
Major Application
diagnostic assay manufacturinghematologyhistology
InChI
InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)
InChIKey
YVPYQUNUQOZFHG-UHFFFAOYSA-N
SMILES
C(O)(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I
LogP
3.3 at · 3.3 at 20℃
FDA UNII
5 UVC90J1LK · 5UVC90J1LK
EPA Substance Registry System
3 · Benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo- (117-96-4)
UNSPSC Code
12352207 · 12352207
NACRES
75 · NA.75
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
334 · H334-H317
Precautionary statements
261 · P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P261-P285-P304+P341-P342+P311-P501
PPE
95 · Eyeshields, Gloves, type N95 (US)
WGK Germany
3 · 3
RTECS
5950000 · DG5950000
HS Code
2924.29 · 2924.29.7790
Storage Class
11 · 11 - Combustible Solids
Hazardous Substances Data
117 · 117-96-4(Hazardous Substances Data)
Toxicity
50 intravenous · LD50 intravenous in mouse: 8900mg/kg
REACH Registrations
Active

The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Diatrizoate sodium is included on this list. /Diatrizoate sodium/

For more FDA Requirements (Complete) data for DIATRIZOATE (6 total), please visit the HSDB record page.

Hazard Classes and CategoriesSkin Sens. 1 (90%)
Skin, Eye, and Respiratory IrritationsAdverse effects of intravascular ... diatrizoate sodium include nasal and conjunctival symptoms (e.g., rhinitis, lacrimation, sneezing).

Safety & protection

Storage ConditionsProtect from light. Store at 20-25 °C (68-77 °F); avoid excessive heat.
Disposal Methods · 1 item

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Toxicology

Interactions · 5 items

Neurologic effects, including paraplegia, of diatrizoates may increase during aortography when diatrizoates are administered after hypertensive agents used to increase contrast; this increase is due to contraction of vessels in the splanchic circulation, which forces more of the contrast material into the vessels leading to the spine and spinal cord.

Incidence of delayed (more than 1 hour after administration) reactions (eg. hypersensitivity, fever, skin rash, flu-like symptoms, joint pain, flushing, pruritus, emesis, hypotension, dizziness) to intravenous contrast media may be increased in patients who have received interleukin-2; some symptoms may resemble a "recall" reaction to interleukin-2; supportive medical treatment may be necessary if symptoms are significant; there is some evidence that incidence is reduced if contrast media administration is delayed until 6 weeks after interleukin-2 administration.

Concurrent use /of chymopapain/ with diatrizoates may increase the risk of toxicity, especially if either agent enters the subarachnoid space; it is strongly recommended that diskography not be performed as part of the chemonucleolysis procedure.

Concurrent intravascular administration of diatrizoates with beta-adrenergic blocking agents may increase the risk of moderate to severe anaphylactoid reaction; also, hypotensive effects may be exacerbated; discontinuation of the beta-adrenergic blocking agent may be advisable before administration of contrast media in patients with other risk factors.

For more Interactions (Complete) data for DIATRIZOATE (9 total), please visit the HSDB record page.

Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that diatrizoate is expected to have very high mobility in soil(SRC). The estimated pKa of diatrizoate is 1.13(3), indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization from moist soil is not expected because the compound exists as an anion and anions do not volatilize. Diatrizoate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.6X10-15 mm Hg at 25 °C(SRC), determined from a fragment constant method(5). Iodinated X-ray contrast agents are considered nondegradable by microorganisms(6).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that diatrizoate is not expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 1.13(3) indicates diatrizoate will exist almost entirely in the anion form at pH values of 5 to 9 and, therefore, volatilization from water or moist soil surfaces is not expected to be an important fate process(SRC). According to a classification scheme(4), an estimated BCF of 3(SRC), from an estimated log Kow of 1.37(5) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Iodinated X-ray contrast agents are considered nondegradable by microorganisms(7).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), diatrizoate, which has an estimated vapor pressure of 3.8X10-15 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase diatrizoate may be removed from the air by wet or dry deposition(SRC). Diatrizoate does not contain chromophores that absorb at wavelengths >290 nm(4) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).

Milk ConcentrationsAlthough problems in humans have not been documented, since diatrizoates are distributed unchanged into breast milk, temporary discontinuation of breast-feeding is recommended for at least 24 hours following administration.
Effluent Concentrations · 1 item

Diatrizoate was found in outflow from a municipal sewage treatment plant in Germany monitored from 1996-1998; the average concentration was 0.08 ug/L with a maximum of 8.7 ug/L reported; the 90th percentile concentration was 1.5 ug/L, and 22 of 25 samples were above the detection limit of 0.010 ug/L(1). The compound was detected at a concentration of 4 ug/L in surface water treatment employing bank filtration(2). Diatrizoate was detected at a concentration range of approximately 210 to 1.0X10+6 ng/L in an industrial waste water of the Netherlands in 2002. Total riverine discharge was estimated at 8.989 tons/yr in 2002(3). The average concentration of diatrizoate in six sewage treatment works in the United Kingdom sampled in 2001 was 42.1 ng/L; detection limit = 24.0 ng/L(4).

Soil Adsorption/Mobility · 1 item

Using a structure estimation method based on molecular connectivity indices(1), the Koc of diatrizoate can be estimated to be 10(SRC). According to a classification scheme(2), this estimated Koc value suggests that diatrizoate is expected to have very high mobility in soil. Iodinated diagnostic contrast agents such as diatrizoate leach readily into groundwater(3). The estimated pKa of diatrizoate is 1.13(4), indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(5).

Human Toxicity Excerpts · 5 items

/SIGNS AND SYMPTOMS/ Anaphylactic reactions: Anaphylactic reactions, including fatalities, have been reported with the use of Gastrografin. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies). Medical personnel trained in the treatment of anaphylactic reactions and the necessary drugs and medical equipment should always be readily available when Gastrografin is used.

/SIGNS AND SYMPTOMS/ Neurologic effects, including paraplegia, of diatrizoates may increase during aortography when diatrizoates are administered after hypertensive agents used to increase contrast; this increase is due to contraction of vessels in the splanchic circulation, which forces more of the contrast material into the vessels leading to the spine and spinal cord.

/SIGNS AND SYMPTOMS/ Other adverse effects of intravascular diatrizoate meglumine and diatrizoate sodium include nasal and conjunctival symptoms (e.g., rhinitis, lacrimation, sneezing), urticaria, pruritus, rash, angioedema, edema, weakness, pallor, cramps, sweating, severe retching and choking, and metallic taste. Neutropenia, erythrocyte sludging and agglutination, crenation, and transient changes in coagulation may occur; rarely disseminated intravascular coagulation resulting in death has been reported. Infrequently, immediate or delayed chills can occur, sometimes with fever. Salivary gland swelling may occur a few hours to 4 days after administration of the medium and persist several days.

/SIGNS AND SYMPTOMS/ Arteriography of arterial trunks providing blood supply to spinal-artery branches or selective spinal arteriography can cause mild to severe muscle spasm; severe neurologic reactions including permanent paralysis, paraplegia, and quadriplegia have occasionally been reported

For more Human Toxicity Excerpts (Complete) data for DIATRIZOATE (18 total), please visit the HSDB record page.

Artificial Pollution SourcesDiatrizoate's production and use as a diagnostic contrast agent(1) may result in its release to the environment through various waste streams(SRC).
Environmental Biodegradation · 1 item

AEROBIC: Iodinated X-ray contrast agents are considered nondegradable by microorganisms(1,2). However when incubated with 1mM diatrizoate at 30 °C for 32 days, the fungus Trametes versicolor, has been shown to partially diiodinate C-14 ring-labeled diatrizoate, liberating traces of 14-CO2(1). The three main metabolites identified were 3,5-di(acetamido)-2,6-diiodobenzoic acid, 3,5-di(acetamido)-2,4-diiodobenzoic acid, and 3,5-di(acetamido)-2-iodobenzoic acid(1).

Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

diatrizoate

DILI Negative

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Environmental Bioconcentration · 1 item

An estimated BCF of 3 was calculated in fish for diatrizoate(SRC), using an estimated log Kow of 1.37(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 item

The estimated pKa of diatrizoate is 1.13(1), indicating that this compound will primarily exist as an anion in the aqueous environment and anions do not volatilize from water or moist soil surfaces. Diatrizoate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.6X10-15 mm Hg(SRC), determined from a fragment constant method(2).

Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Acute Exposure/ Hemodynamic changes and contrast nephropathy are well known complications of contrast media injection. However, the mechanisms of toxicity leading to these complications remain unclear. /It was/ hypothesized that contrast media toxicity would manifest as a change in antioxidant enzyme activity, thus leading to tissue damage.This study investigated the effects of injection of ionic high-osmolar diatrizoate, ionic low-osmolar ioxaglate, and nonionic low-osmolar iopromide on the activities of two antioxidant enzymes, glutathione peroxidase (GPX) and superoxide dismutase (SOD), in the heart and kidney tissue of normal male Wistar rats (n = 51) and streptozotocin (STZ)-induced diabetic rats (n = 54). Activities of GPX and SOD were assayed spectrophotometrically. Renal GPX activities were significantly decreased in both normal (458.3 +/- 64.6 to 385.5 +/- 63.4 mU/mg, p = 0.005) and diabetic rats (669.0 +/- 98.1 vs. 564.0 +/- 153.3 mU/mg, p = 0.035) at 1 hour after diatrizoate injection. Renal SOD activities were not affected after contrast injection. Ioxaglate and iopromide injection did not cause any change in renal antioxidant enzyme activity. In contrast to kidney tissue, there was no significant change in GPX and SOD activities in heart tissue at 1 hour after injection of different contrast media. Intravenous injection of ionic high-osmolar diatrizoate reduced renal GPX activity during the first hour in both normal and STZ-induced diabetic rats. Heart tissue was not prone to antioxidant enzyme activity changes after intravenous contrast media injection. GPX activity reduction can be an important mechanism of nephrotoxicity after contrast media injection.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ The biological effects of iodinated contrast media were examined by using spermatogenesis in mouse testis as the experimental model. Spermhead survival and abnormality assays were used as the biological end points. Diatrizoate meglumine/diatrizoate sodium and iopamidol were administered intravenously at equal rates and concentrations. Testicular uptake and clearance of these contrast agents were examined by high-performance liquid chromatography techniques. Appropriate mannitol solutions were employed as osmolality controls. Intravenous administration of the contrast agent or its respective mannitol control resulted in approximately a 30% decrease in spermhead count. A dose-related experiment with mannitol demonstrated that the spermhead count decreased rapidly until 600 mOsm/kg was reached, beyond which this decrease was minimal. Clearance of both contrast media was complete in approximately 4 hours. No significant increase in the induction of spermhead abnormalities was observed. Osmotic substances, such as iodinated contrast agents, affect the process of spermatogenesis.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ No teratogenic effects attributable to diatrizoate meglumine or diatrizoate sodium have been observed in teratology studies performed in animals.

Regulatory information

FDA Requirements · 5 items

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl diatrizoate meglumine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Diatrizoate meglumine/

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl diatrizoate sodium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Diatrizoate sodium/

The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Diatrizoate meglumine is included on this list. /Diatrizoate meglumine/

The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Diatrizoate sodium is included on this list. /Diatrizoate sodium/

For more FDA Requirements (Complete) data for DIATRIZOATE (6 total), please visit the HSDB record page.

Safety data

PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
rtecs
DG5950000
hs_code
2924.29.7790
Toxicity
LD50 intravenous in mouse: 8900mg/kg
Signal word
Danger
Symbol(GHS)
GHS08
Storage Class
11 - Combustible Solids
Hazard statements
H334-H317
REACH Registrations
Active
Precautionary statements
P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P261-P285-P304+P341-P342+P311-P501
Hazardous Substances Data
117-96-4(Hazardous Substances Data)
Biological Half-Life · 1 item

Following rapid IV injection of diatrizoate sodium in patients with normal renal function, blood drug concentrations peak immediately, fall rapidly within 5-10 minutes, and then decline with a halflife of about 30-60 minutes. In patients with severely impaired renal function, the blood drug halflife is reported to be 20-140 hours.

Metabolism/Metabolites · 1 item

The metabolic behavior of 3-amino-5-acetamido-2,4,6-triiodobenzoate and 3,5-diamino-2,4,6 -triiodobenzoate was examined. Drug retention in rabbits was monitored with a gamma camera. Diatrizoate was partially deacetylated by liver microsomes to 3-amino-5-acetamido-2,4,6-triiodobenzoate and 3,4-diamino-2,4,6-triiodobenzoate. The rabbit converted some of 3,5-diamino-2,4,6-trioodobenzoate to a urinary metabolite which was similar to that formed by liver microsomes.

FDA Pharmacological Classification · 5 items

5UVC90J1LK

DIATRIZOIC ACID

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Diatrizoic acid is a Radiographic Contrast Agent. The mechanism of action of diatrizoic acid is as a X-Ray Contrast Activity.

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 6 items

However, it is not metabolized but excreted unchanged in the urine, each diatrizoate molecule remaining "obligated" to its sodium moiety. The liver and small intestine provide the major alternate route of excretion for diatrizoate. Injectable radiopaque diagnostic agents are excreted unchanged in human milk. Saliva is a minor secretory pathway for injectable radiopaque diagnostic agents.

Diatrizoate meglumine is excreted in breast milk following intravascular administration.

Diatrizoate sodium is very poorly absorbed from the GI tract. In some patients, especially infants and patients with engorgement of the intestinal mucosa, small amounts of the drug may be absorbed from the GI tract and occasionally produce partial visualization of the urinary tract. Following intravesical instillation of diatrizoate sodium, only small amounts of the drug are absorbed into blood through the bladder. Some absorption of diatrizoate sodium into blood may also occur through serous membranes such as the peritoneum or pleura. The drug is rapidly absorbed after IM or subcutaneous injection.

Diatrizoate sodium is rapidly distributed throughout extracellular fluid following intravascular administration. Less than 5% of the drug appears to be bound to plasma proteins.

Diatrizoates, when administered intravenously, cross the placenta and are evenly distributed in fetal tissues. Intra-amniotic injection of diatrizoates has been reported to suppress the fetal thyroid gland.

For more Absorption, Distribution and Excretion (Complete) data for DIATRIZOATE (7 total), please visit the HSDB record page.

Cellular LocationsMembrane

Uses & manufacturing

Uses · 4 items

Density gradient reagent for blood cell separation. /Sodium diatrizoate/

MEDICATION

MEDICATION (VET)

Use (kg) in Switzerland (2009): >25

U.S. Exports · 2 items

(1975) No Data

(1977) No Data

U.S. Imports · 2 items

(1975) No Data

(1977) No Data

U.S. Production · 2 items

(1975) GREATER THAN 1.82X10+6 G (SALTS ONLY)

(1977) GREATER THAN 9.08X10+5 G (SALTS ONLY)

Methods of Manufacturing · 3 items

Derived from benzoic acid by (1) nitration to the 3,5-dinitro acid, (2) reduction by means of stannous chloride or other reducing agent to the corresponding diamino acid, (3) iodination with iodine monochloride in acetic acid to the 2,4,6-triiodo derivative, or (4) acetylation of the amino groups by use of acetic anhydride.

Diatrizoic acid is reacted with equimolar quantity of NaOH, usually in water for injection to produce soln of required concn. /Sodium diatrizoate/

Diatrizoic acid is reacted with an equimolar quantity of methylglucamine (meglumine), usually in water for injection, to produce a solution of the required concentration. /Diatrizoate meglumine/

Formulations/Preparations · 2 items

66% (660 mg per mL) of diatrizoate meglumine and 10% (100 mg per mL) of diatrizoate sodium with 36.7% (367 mg per mL) of iodine (Rx) /Tradename:/ Gastrografin; MD-Gastroview. /Diatrizoates/

GRADE: USP (as solution for injection) /Sodium diatrizoate/

General Manufacturing Information · 4 items

Information available in 2005 indicated that Meglumine diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States, Yugoslavia (1,2) /Meglumine diatrizoate/

Information available in 2005 indicated that Sodium diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States, Yugoslavia (1,2) /Meglumine diatrizoate/

Information available in 2005 indicated that Lysine diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Austria, Germany, Hungary (1,2)

Information available in 2005 indicated that Calcium diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Brazil, Spain (1,2)

Applications · 4 items

UsesDiatrizoic acid is a gradient reagent used for blood cell separation and diagnostic aid (radiopaque medium). Diatrizoic acid may be used as an alternative to barium sulfate for medical imaging of the gastrointestinal tract, such as upper gastrointestinal series and small bowel series.

UsesDensity gradient reagent for blood cell seperation. Diagnostic aid (radiopaque medium)

Usesradiopaque agent

General DescriptionDiatrizoate is a water-soluble, ionicmonomer. It is commercially available as the megluminesalt, sodium salt, or as fixed combinations of the two saltforms. These triiodobenzoic acid salts contain 47% organicallybound iodine.Numerous products with various concentrations of one ortwo of the salt forms are available for various imaging procedures.Indicated uses include angiography, venography,excretory urography, retrograde cystourethrography, retrogradeor ascending pyelography, operative, T-tube, or percutaneoustranshepatic cholangiography, splenoportography,arthrography; discography, radiographic examinationof the GI tract when barium sulfate is contraindicated (i.e.,suspected perforation of the GI tract), adjunct contrast enhancementin CT of the torso (dual contrast study), and hysterosalpingography.

Upstream & downstream products

Upstream raw materials

3,5-Diaminobenzoic acidACETYL IODIDESodium hydroxideHydrogen2-Chloro-3,5-dinitrobenzoic acidIodine monochloride

Downstream products

Diatrizoate sodium
Additional notes · 1 item

DefinitionChEBI: A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an -ray contrast medium in gastrointestinal studies, angiography, and urography.

/LABORATORY ANIMALS: Neurotoxicity/ The neurotoxicity of Iohexol was evaluated and compared with the neurotoxicity of sodium diatrizoate. Direct neurotoxicity was evaluated with in vitro rat hippocampal slices, and angiographic neurotoxicity was studied in a cat's spinal cord following thoracic aortography. Sodium diatrizoate caused early excitatory changes in electrical activity and later inhibition in the experiments with the rat brain slices while the cat's spinal cord experiments showed an increase in the ventral root reflexes.

For more Non-Human Toxicity Excerpts (Complete) data for DIATRIZOATE (8 total), please visit the HSDB record page.